# InheRET: A SaaS solution to identify patients at increased risk for hereditary disease.

> **NIH NIH R42** · INHERET, INC · 2021 · $995,667

## Abstract

PROJECT SUMMARY
This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of
patients at increased risk for hereditary disease, adding patient navigation features and customizable database
entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0
followed by pilot testing in 5 diverse clinics. InheRET's aim is to quickly and easily identify individuals at
increased risk for hereditary diseases enabling them to access downstream care, reducing morbidity and
mortality. InheRET's unique features reduces clinical ascertainment barriers, streamlines workflows and
enhances profitability within health systems. The aims for this project are to complete in silico (computer
generated) testing of the cognitive computing engine of InheRET followed retrospective testing and finally, pilot
testing in a variety of clinical settings to determine if any additional changes are needed to the product prior to
commercialization. In addition, we will expand the integration of the InheRET program with an EPIC electronic
health record system, providing hard and/or soft alerts for providers as patient reports become available.
Success will be determined if we achieve 100% concordance with the in silico testing (i.e. the cognitive
computing engine functions correctly), 98% concordance with clinical determinations in the clinical pilot testing,
and 100% concordance in the integration testing (all patient reports are appropriately and seamlessly routed to
the proper medical records).
Our primary objective is to produce an accurate, easy-to-use and understandable report to ensure patients
who may unknowingly harbor inherited genetic mutations are identified, thereby enabling them to access
genetic counselors and testing along with appropriate downstream care. While both patient and physician
reports are provided, the physician reports will be enhanced by providing recommended genes for testing with
streamlined ordering processes. By doing so, patients can reduce their risk of disease, receive tailored
treatment if they incur disease, and reduce overall mortality.

## Key facts

- **NIH application ID:** 10260583
- **Project number:** 5R42CA239842-03
- **Recipient organization:** INHERET, INC
- **Principal Investigator:** David Freeman Keren
- **Activity code:** R42 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $995,667
- **Award type:** 5
- **Project period:** 2019-05-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260583

## Citation

> US National Institutes of Health, RePORTER application 10260583, InheRET: A SaaS solution to identify patients at increased risk for hereditary disease. (5R42CA239842-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10260583. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*